Shares of Clene, Inc. surged Thursday after the company released “golden” data from an interim analysis of a Phase II study.
Clene recently announced top-line data from RESCUE-ALS, a Phase 2 clinical trial evaluating CNM-Au8 as a disease modifying treatment for people with early amyotrophic lateral sclerosis (ALS).